Literature DB >> 25907815

Baseline characteristics of patients predicting suitability for rapid naltrexone induction.

Shanthi Mogali1, Nabil A Khan1, Esther S Drill2, Martina Pavlicova2, Maria A Sullivan, Edward Nunes1,3, Adam Bisaga1,3.   

Abstract

BACKGROUND AND OBJECTIVES: Extended-release (XR) injection naltrexone has proved promising in the treatment of opioid dependence. Induction onto naltrexone is often accomplished with a procedure known as rapid naltrexone induction. The purpose of this study was to evaluate pre-treatment patient characteristics as predictors of successful completion of a rapid naltrexone induction procedure prior to XR naltrexone treatment.
METHODS: A chart review of 150 consecutive research participants (N = 84 completers and N = 66 non-completers) undergoing a rapid naltrexone induction with the buprenorphone-clonidine procedure were compared on a number of baseline demographic, clinical and psychosocial factors. Logistic regression was used to identify client characteristics that may predict successful initiation of naltrexone after a rapid induction-detoxification.
RESULTS: Patients who failed to successfully initiate naltrexone were younger (AOR: 1.040, CI: 1.006, 1.075), and using 10 or more bags of heroin (or equivalent) per day (AOR: 0.881, CI: 0.820, 0.946). Drug use other than opioids was also predictive of failure to initiate naltrexone in simple bivariate analyses, but was no longer significant when controlling for age and opioid use level.
CONCLUSIONS: Younger age, and indicators of greater substance dependence severity (more current opioid use, other substance use) predict difficulty completing a rapid naltrexone induction procedure. Such patients might require a longer period of stabilization and/or more gradual detoxification prior to initiating naltrexone. SCIENTIFIC SIGNIFICANCE: Our study findings identify specific characteristics of patients who responded positively to rapid naltrexone induction. © American Academy of Addiction Psychiatry.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25907815      PMCID: PMC4496800          DOI: 10.1111/ajad.12180

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  8 in total

1.  Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

Authors:  Brantley P Jarvis; August F Holtyn; Meredith S Berry; Shrinidhi Subramaniam; Annie Umbricht; Michael Fingerhood; George E Bigelow; Kenneth Silverman
Journal:  J Subst Abuse Treat       Date:  2017-04-20

2.  Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine.

Authors:  Maria Sullivan; Adam Bisaga; Martina Pavlicova; C Jean Choi; Kaitlyn Mishlen; Kenneth M Carpenter; Frances R Levin; Elias Dakwar; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2017-01-10       Impact factor: 18.112

3.  Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.

Authors:  Arthur Robin Williams; Vincent Barbieri; Kaitlyn Mishlen; Frances R Levin; Edward V Nunes; John J Mariani; Adam Bisaga
Journal:  Am J Addict       Date:  2017-03-22

4.  Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.

Authors:  Matisyahu Shulman; Mei-Chen Hu; Maria A Sullivan; Sarah C Akerman; James Fratantonio; Vincent Barbieri; Edward V Nunes; Adam Bisaga
Journal:  Drug Alcohol Depend       Date:  2022-02-02       Impact factor: 4.492

Review 5.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

6.  Ethical and clinical safety considerations in the design of an effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence.

Authors:  Edward V Nunes; Joshua D Lee; Dominic Sisti; Andrea Segal; Arthur Caplan; Marc Fishman; Genie Bailey; Gregory Brigham; Patricia Novo; Sarah Farkas; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-09-28       Impact factor: 2.226

7.  A Randomized Trial Comparing Extended-Release Injectable Suspension and Oral Naltrexone, Both Combined With Behavioral Therapy, for the Treatment of Opioid Use Disorder.

Authors:  Maria A Sullivan; Adam Bisaga; Martina Pavlicova; Kenneth M Carpenter; C Jean Choi; Kaitlyn Mishlen; Frances R Levin; John J Mariani; Edward V Nunes
Journal:  Am J Psychiatry       Date:  2018-10-19       Impact factor: 18.112

8.  Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.

Authors:  Paolo Mannelli; Antoine B Douaihy; Sarah C Akerman; Anna Legedza; James Fratantonio; Abigail Zavod; Maria A Sullivan
Journal:  Am J Addict       Date:  2022-02-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.